Boya Peng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Boya Peng has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Minh T. N. Le
Department of Pharmacology Yong Loo Lin School of Medicine National University of Singapore Singapore Singapore
9 shared publications Migara Kavishka Jayasinghe
Institute for Digital Medicine and Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore
5 shared publicationsBing Liu
National-Regional Key Technology Engineering Laboratory for Synthetic Biology of Medicine, Cancer Research Center, Shenzhen University, Shenzhen, China
3 shared publicationsAnh Hong Le
Institute for Digital Medicine and Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore
2 shared publicationsChunmei Guo
Department of Biotechnology, Dalian Medical University, 9 West Section, Lvshun Southern Road, Dalian 116044, China
2 shared publicationsGuangyi Jin
School of Medicine, Shenzhen University, Shenzhen 518060, China
2 shared publications
Latest Publications
- 26 November 2025
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 218, 105053
Breaking barriers: Extracellular vesicles as dual-agents in diagnosing and treating brain metastasis
- 26 November 2025
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 218, 105053
Breaking barriers: Extracellular vesicles as dual-agents in diagnosing and treating brain metastasis
- Open Access
- 27 September 2025
- Published by Elsevier in Molecular Therapy
- Vol. 34 (1) , 68-96
Designing nucleic acid-based therapeutics for cancer treatment: Updates on the state of the art
- 27 September 2025
- Published by Elsevier in Molecular Therapy
- Vol. 34 (1) , 68-96
Open AccessDesigning nucleic acid-based therapeutics for cancer treatment: Updates on the state of the art
- Open Access
- 19 September 2023
- Published by Wiley in Cell Proliferation
- Vol. 57 (2) , e13549
Activation of S1P2 is protective against cisplatin‐induced peripheral neuropathy
- 19 September 2023
- Published by Wiley in Cell Proliferation
- Vol. 57 (2) , e13549
Open AccessActivation of S1P2 is protective against cisplatin‐induced peripheral neuropathy
- Open Access
- 8 August 2023
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 12 (8) , e12354
Endocytosis of red blood cell extracellular vesicles by macrophages leads to cytoplasmic heme release and prevents foam cell formation in atherosclerosis
Extracellular vesicles (EVs) can be produced from red blood cells (RBCs) on a large scale and used to deliver therapeutic payloads efficiently. However, not much is known about the native biological properties of RBCEVs. Here, we demonstrate that RBCEVs are primarily taken up by macrophages and monocytes. This uptake is an active process, mediated mainly by endocytosis. Incubation of CD14+ monocytes with RBCEVs induces their differentiation into macrophages with an Mheme‐like phenotype, characterized by upregulation of heme oxygenase‐1 (HO‐1) and the ATP‐binding cassette transporter ABCG1. Moreover, macrophages that take up RBCEVs exhibit a reduction in surface CD86 and decreased secretion of TNF‐α under inflammatory stimulation. The upregulation of HO‐1 is attributed to heme derived from haemoglobin in RBCEVs. Heme is released from internalized RBCEVs in late endosomes and lysosomes via the heme transporter, HRG1. Consequently, RBCEVs exhibit the ability to attenuate foam cell formation from oxidized low‐density lipoproteins (oxLDL)‐treated macrophages in vitro and reduce atherosclerotic lesions in ApoE knockout mice on a high‐fat diet. In summary, our study reveals the uptake mechanism of RBCEVs and their delivery of heme to macrophages, suggesting the potential application of RBCEVs in the treatment of atherosclerosis.
- 8 August 2023
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 12 (8) , e12354
Open AccessEndocytosis of red blood cell extracellular vesicles by macrophages leads to cytoplasmic heme release and prevents foam cell formation in atherosclerosis
Extracellular vesicles (EVs) can be produced from red blood cells (RBCs) on a large scale and used to deliver therapeutic payloads efficiently. However, not much is known about the native biological properties of RBCEVs. Here, we demonstrate that RBCEVs are primarily taken up by macrophages and monocytes. This uptake is an active process, mediated mainly by endocytosis. Incubation of CD14+ monocytes with RBCEVs induces their differentiation into macrophages with an Mheme‐like phenotype, characterized by upregulation of heme oxygenase‐1 (HO‐1) and the ATP‐binding cassette transporter ABCG1. Moreover, macrophages that take up RBCEVs exhibit a reduction in surface CD86 and decreased secretion of TNF‐α under inflammatory stimulation. The upregulation of HO‐1 is attributed to heme derived from haemoglobin in RBCEVs. Heme is released from internalized RBCEVs in late endosomes and lysosomes via the heme transporter, HRG1. Consequently, RBCEVs exhibit the ability to attenuate foam cell formation from oxidized low‐density lipoproteins (oxLDL)‐treated macrophages in vitro and reduce atherosclerotic lesions in ApoE knockout mice on a high‐fat diet. In summary, our study reveals the uptake mechanism of RBCEVs and their delivery of heme to macrophages, suggesting the potential application of RBCEVs in the treatment of atherosclerosis.
- Top Cited Papers
- 10 March 2023
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 17 (6) , 5187-5210
Advances in Drug Delivery Systems Based on Red Blood Cells and Their Membrane-Derived Nanoparticles
Red blood cells (RBCs) and RBC membrane-derived nanoparticles have been historically developed as bioinspired drug delivery systems to combat the issues of premature clearance, toxicity, and immunogenicity of synthetic nanocarriers. RBC-based delivery systems possess characteristics including biocompatibility, biodegradability, and long circulation time, which make them suited for systemic administration. Therefore, they have been employed in designing optimal drug formulations in various preclinical models and clinical trials to treat a wide range of diseases. In this review, we provide an overview of the biology, synthesis, and characterization of drug delivery systems based on RBCs and their membrane including whole RBCs, RBC membrane-camouflaged nanoparticles, RBC-derived extracellular vesicles, and RBC hitchhiking. We also highlight conventional and latest engineering strategies, along with various therapeutic modalities, for enhanced precision and effectiveness of drug delivery. Additionally, we focus on the current state of RBC-based therapeutic applications and their clinical translation as drug carriers, as well as discussing opportunities and challenges associated with these systems.
- 10 March 2023
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 17 (6) , 5187-5210
Top Cited PapersAdvances in Drug Delivery Systems Based on Red Blood Cells and Their Membrane-Derived Nanoparticles
Red blood cells (RBCs) and RBC membrane-derived nanoparticles have been historically developed as bioinspired drug delivery systems to combat the issues of premature clearance, toxicity, and immunogenicity of synthetic nanocarriers. RBC-based delivery systems possess characteristics including biocompatibility, biodegradability, and long circulation time, which make them suited for systemic administration. Therefore, they have been employed in designing optimal drug formulations in various preclinical models and clinical trials to treat a wide range of diseases. In this review, we provide an overview of the biology, synthesis, and characterization of drug delivery systems based on RBCs and their membrane including whole RBCs, RBC membrane-camouflaged nanoparticles, RBC-derived extracellular vesicles, and RBC hitchhiking. We also highlight conventional and latest engineering strategies, along with various therapeutic modalities, for enhanced precision and effectiveness of drug delivery. Additionally, we focus on the current state of RBC-based therapeutic applications and their clinical translation as drug carriers, as well as discussing opportunities and challenges associated with these systems.
- Open Access
- 16 April 2022
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 11 (4) , e12187
Robust delivery of RIG‐I agonists using extracellular vesicles for anti‐cancer immunotherapy
The RIG‐I pathway can be activated by RNA containing 5′ triphosphate, leading to type I interferon release and immune activation. Hence, RIG‐I agonists have been used to induce immune responses against cancer as potential immunotherapy. However, delivery of 5′ triphosphorylated RNA molecules as RIG‐I agonists to tumour cells in vivo is challenging due to the susceptibility of these molecules to degradation. In this study, we demonstrate the use of extracellular vesicles (EVs) from red blood cells (RBCs), which are highly amenable for RNA loading and taken up robustly by cancer cells, for RIG‐I agonist delivery. We evaluate the anti‐cancer activity of two novel RIG‐I agonists, the immunomodulatory RNA (immRNA) with a unique secondary structure for efficient RIG‐I activation, and a 5′ triphosphorylated antisense oligonucleotide with dual function of RIG‐I activation and miR‐125b inhibition (3p‐125b‐ASO). We find that RBCEV‐delivered immRNA and 3p‐125b‐ASO trigger the RIG‐I pathway, and induce cell death in both mouse and human breast cancer cells. Furthermore, we observe a significant suppression of tumour growth coupled with increased immune cell infiltration mediated by the activation of RIG‐I cascade after multiple intratumoral injections of RBCEVs loaded with immRNA or 3p‐125b‐ASO. Targeted delivery of immRNA using RBCEVs with EGFR‐binding nanobody administrated via intrapulmonary delivery facilitates the accumulation of RBCEVs in metastatic cancer cells, leading to potent tumour‐specific CD8+ T cells immune response. This contributes to prominent suppression of breast cancer metastasis in the lung. Hence, this study provides a new strategy for efficient RIG‐I agonist delivery using RBCEVs for immunotherapy against cancer and cancer metastasis.
- 16 April 2022
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 11 (4) , e12187
Open AccessRobust delivery of RIG‐I agonists using extracellular vesicles for anti‐cancer immunotherapy
The RIG‐I pathway can be activated by RNA containing 5′ triphosphate, leading to type I interferon release and immune activation. Hence, RIG‐I agonists have been used to induce immune responses against cancer as potential immunotherapy. However, delivery of 5′ triphosphorylated RNA molecules as RIG‐I agonists to tumour cells in vivo is challenging due to the susceptibility of these molecules to degradation. In this study, we demonstrate the use of extracellular vesicles (EVs) from red blood cells (RBCs), which are highly amenable for RNA loading and taken up robustly by cancer cells, for RIG‐I agonist delivery. We evaluate the anti‐cancer activity of two novel RIG‐I agonists, the immunomodulatory RNA (immRNA) with a unique secondary structure for efficient RIG‐I activation, and a 5′ triphosphorylated antisense oligonucleotide with dual function of RIG‐I activation and miR‐125b inhibition (3p‐125b‐ASO). We find that RBCEV‐delivered immRNA and 3p‐125b‐ASO trigger the RIG‐I pathway, and induce cell death in both mouse and human breast cancer cells. Furthermore, we observe a significant suppression of tumour growth coupled with increased immune cell infiltration mediated by the activation of RIG‐I cascade after multiple intratumoral injections of RBCEVs loaded with immRNA or 3p‐125b‐ASO. Targeted delivery of immRNA using RBCEVs with EGFR‐binding nanobody administrated via intrapulmonary delivery facilitates the accumulation of RBCEVs in metastatic cancer cells, leading to potent tumour‐specific CD8+ T cells immune response. This contributes to prominent suppression of breast cancer metastasis in the lung. Hence, this study provides a new strategy for efficient RIG‐I agonist delivery using RBCEVs for immunotherapy against cancer and cancer metastasis.
- 1 September 2021
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 74, 62-78
New approaches in extracellular vesicle engineering for improving the efficacy of anti-cancer therapies
- 1 September 2021
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 74, 62-78
New approaches in extracellular vesicle engineering for improving the efficacy of anti-cancer therapies
- Open Access
- 17 December 2020
- Published by Wiley in Cell Proliferation
- Vol. 54 (2) , e12913
Essential functions of miR‐125b in cancer
MicroRNAs (miRNAs) are small and highly conserved non‐coding RNAs that silence target mRNAs, and compelling evidence suggests that they play an essential role in the pathogenesis of human diseases, especially cancer. miR‐125b, which is the mammalian orthologue of the first discovered miRNA lin‐4 in Caenorhabditis elegans, is one of the most important miRNAs that regulate various physiological and pathological processes. The role of miR‐125b in many types of cancer has been well established, and so here we review the current knowledge of how miR‐125b is deregulated in different types of cancer; its oncogenic and/or tumour‐suppressive roles in tumourigenesis and cancer progression; and its regulation with regard to treatment response, all of which are underlined in multiple studies. The emerging information that elucidates the essential functions of miR‐125b might help support its potentiality as a diagnostic and prognostic biomarker as well as an effective therapeutic tool against cancer.
- 17 December 2020
- Published by Wiley in Cell Proliferation
- Vol. 54 (2) , e12913
Open AccessEssential functions of miR‐125b in cancer
MicroRNAs (miRNAs) are small and highly conserved non‐coding RNAs that silence target mRNAs, and compelling evidence suggests that they play an essential role in the pathogenesis of human diseases, especially cancer. miR‐125b, which is the mammalian orthologue of the first discovered miRNA lin‐4 in Caenorhabditis elegans, is one of the most important miRNAs that regulate various physiological and pathological processes. The role of miR‐125b in many types of cancer has been well established, and so here we review the current knowledge of how miR‐125b is deregulated in different types of cancer; its oncogenic and/or tumour‐suppressive roles in tumourigenesis and cancer progression; and its regulation with regard to treatment response, all of which are underlined in multiple studies. The emerging information that elucidates the essential functions of miR‐125b might help support its potentiality as a diagnostic and prognostic biomarker as well as an effective therapeutic tool against cancer.
- Open Access
- 14 April 2019
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 8 (1) , 1599680
Tumor‐secreted extracellular vesicles promote the activation of cancer‐associated fibroblasts via the transfer of microRNA‐125b
Tumour cells release large quantities of extracellular vesicles (EVs) to mediate their interactions with other cells in the tumour microenvironment. To identify host cells that naturally take up EVs from tumour cells, we created breast cancer cell lines secreting fluorescent EVs. These fluorescent EVs are taken up most robustly by fibroblasts within the tumour microenvironment. RNA sequencing indicated that miR‐125b is one of the most abundant microRNAs secreted by mouse triple‐negative breast cancer 4T1 and 4TO7 cells. Treatment with 4T1 EVs leads to an increase in fibroblast activation in isogenic 4TO7 tumours, which is reversed by blocking miR‐125b in 4T1 EVs; hence, miR‐125b delivery by EVs is responsible for fibroblast activation in mouse tumour models. miR‐125b is also secreted by human breast cancer cells and the uptake of EVs from these cells significantly increases cellular levels of miR‐125b and expression of multiple cancer‐associated fibroblast markers in resident fibroblasts. Overexpression of miR‐125b in both mouse and human fibroblasts leads to an activated phenotype similar to the knockdown of established miR‐125b target mRNAs. These data indicate that miR‐125b is transferred through EVs from breast cancer cells to normal fibroblasts within the tumour microenvironment and contributes to their development into cancer‐associated fibroblasts.
- 14 April 2019
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 8 (1) , 1599680
Open AccessTumor‐secreted extracellular vesicles promote the activation of cancer‐associated fibroblasts via the transfer of microRNA‐125b
Tumour cells release large quantities of extracellular vesicles (EVs) to mediate their interactions with other cells in the tumour microenvironment. To identify host cells that naturally take up EVs from tumour cells, we created breast cancer cell lines secreting fluorescent EVs. These fluorescent EVs are taken up most robustly by fibroblasts within the tumour microenvironment. RNA sequencing indicated that miR‐125b is one of the most abundant microRNAs secreted by mouse triple‐negative breast cancer 4T1 and 4TO7 cells. Treatment with 4T1 EVs leads to an increase in fibroblast activation in isogenic 4TO7 tumours, which is reversed by blocking miR‐125b in 4T1 EVs; hence, miR‐125b delivery by EVs is responsible for fibroblast activation in mouse tumour models. miR‐125b is also secreted by human breast cancer cells and the uptake of EVs from these cells significantly increases cellular levels of miR‐125b and expression of multiple cancer‐associated fibroblast markers in resident fibroblasts. Overexpression of miR‐125b in both mouse and human fibroblasts leads to an activated phenotype similar to the knockdown of established miR‐125b target mRNAs. These data indicate that miR‐125b is transferred through EVs from breast cancer cells to normal fibroblasts within the tumour microenvironment and contributes to their development into cancer‐associated fibroblasts.
- 27 August 2018
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 54 (77) , 10878-10881
Structural analysis reveals the formation and role of RNA G-quadruplex structures in human mature microRNAs
By employing interdisciplinary approaches, the prevalence, formation, and effect of RNA G-quadruplex (rG4) structures in human microRNAs (miRNAs) are reported.
- 27 August 2018
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 54 (77) , 10878-10881
Structural analysis reveals the formation and role of RNA G-quadruplex structures in human mature microRNAs
By employing interdisciplinary approaches, the prevalence, formation, and effect of RNA G-quadruplex (rG4) structures in human microRNAs (miRNAs) are reported.